Antiretroviral Activity and Safety of Once-Daily Etravirine in Treatment-Naive HIV-Infected Adults: 48-Week Results | Zendy

Michelle Floris-Moore | Zendy; Katie R. Mollan | Zendy; Aimee Wilkin | Zendy; Marc A. Johnson | Zendy; Angela D. M. Kashuba | Zendy; David A. Wohl | Zendy; Kristine B. Patterson | Zendy; Owen Francis | Zendy; Catherine Kronk | Zendy; Joseph J. Eron | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Antiretroviral Activity and Safety of Once-Daily Etravirine in Treatment-Naive HIV-Infected Adults: 48-Week Results

Author(s) -

Michelle Floris-Moore,

Katie R. Mollan,

Aimee Wilkin,

Marc A. Johnson,

Angela D. M. Kashuba,

David A. Wohl,

Kristine B. Patterson,

Owen Francis,

Catherine Kronk,

Joseph J. Eron

Publication year - 2015

Publication title -

antiviral therapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.747

H-Index - 87

eISSN - 2040-2058

pISSN - 1359-6535

DOI - 10.3851/imp2982

Subject(s) - medicine , etravirine , tolerability , dosing , emtricitabine , reverse transcriptase inhibitor , viral load , human immunodeficiency virus (hiv) , adverse effect , immunology , antiretroviral therapy

Etravirine (ETR), a non-nucleoside reverse transcriptase inhibitor approved for 200 mg twice-daily dosing in conjunction with other antiretrovirals (ARVs), has pharmacokinetic properties which support once-daily dosing.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research